120 related articles for article (PubMed ID: 16139802)
1. The novel lipophilic camptothecin analogue gimatecan is very active in vitro in human neuroblastoma: a comparative study with SN38 and topotecan.
Di Francesco AM; Riccardi A; Barone G; Rutella S; Meco D; Frapolli R; Zucchetti M; D'Incalci M; Pisano C; Carminati P; Riccardi R
Biochem Pharmacol; 2005 Oct; 70(8):1125-36. PubMed ID: 16139802
[TBL] [Abstract][Full Text] [Related]
2. Effects of drug efflux proteins and topoisomerase I mutations on the camptothecin analogue gimatecan.
Gounder MK; Nazar AS; Saleem A; Pungaliya P; Kulkarni D; Versace R; Rubin EH
Invest New Drugs; 2008 Jun; 26(3):205-13. PubMed ID: 17943230
[TBL] [Abstract][Full Text] [Related]
3. Subcellular localization of the camptothecin analogues, topotecan and gimatecan.
Croce AC; Bottiroli G; Supino R; Favini E; Zuco V; Zunino F
Biochem Pharmacol; 2004 Mar; 67(6):1035-45. PubMed ID: 15006540
[TBL] [Abstract][Full Text] [Related]
4. Gimatecan and other camptothecin derivatives poison Leishmania DNA-topoisomerase IB leading to a strong leishmanicidal effect.
Prada CF; Alvarez-Velilla R; Balaña-Fouce R; Prieto C; Calvo-Álvarez E; Escudero-Martínez JM; Requena JM; Ordóñez C; Desideri A; Pérez-Pertejo Y; Reguera RM
Biochem Pharmacol; 2013 May; 85(10):1433-40. PubMed ID: 23466420
[TBL] [Abstract][Full Text] [Related]
5. Cellular basis of antiproliferative and antitumor activity of the novel camptothecin derivative, gimatecan, in bladder carcinoma models.
Ulivi P; Zoli W; Fabbri F; Brigliadori G; Ricotti L; Tesei A; Rosetti M; De Cesare M; Beretta GL; Corna E; Supino R; Zunino F
Neoplasia; 2005 Feb; 7(2):152-61. PubMed ID: 15802020
[TBL] [Abstract][Full Text] [Related]
6. A novel oral camptothecin analog, gimatecan, exhibits superior antitumor efficacy than irinotecan toward esophageal squamous cell carcinoma in vitro and in vivo.
Zou J; Li S; Chen Z; Lu Z; Gao J; Zou J; Lin X; Li Y; Zhang C; Shen L
Cell Death Dis; 2018 May; 9(6):661. PubMed ID: 29855512
[TBL] [Abstract][Full Text] [Related]
7. Pattern of antitumor activity of a novel camptothecin, ST1481, in a large panel of human tumor xenografts.
Pratesi G; De Cesare M; Carenini N; Perego P; Righetti SC; Cucco C; Merlini L; Pisano C; Penco S; Carminati P; Vesci L; Zunino F
Clin Cancer Res; 2002 Dec; 8(12):3904-9. PubMed ID: 12473606
[TBL] [Abstract][Full Text] [Related]
8. Potent antitumor activity and improved pharmacological profile of ST1481, a novel 7-substituted camptothecin.
De Cesare M; Pratesi G; Perego P; Carenini N; Tinelli S; Merlini L; Penco S; Pisano C; Bucci F; Vesci L; Pace S; Capocasa F; Carminati P; Zunino F
Cancer Res; 2001 Oct; 61(19):7189-95. PubMed ID: 11585754
[TBL] [Abstract][Full Text] [Related]
9. Cellular bases of the antitumor activity of a 7-substituted camptothecin in hormone-refractory human prostate carcinoma models.
Zuco V; Supino R; De Cesare M; Carenini N; Perego P; Gatti L; Pratesi G; Pisano C; Martinelli R; Bucci F; Zanier R; Carminati P; Zunino F
Biochem Pharmacol; 2003 Apr; 65(8):1281-94. PubMed ID: 12694869
[TBL] [Abstract][Full Text] [Related]
10. Novel stable camptothecin derivatives replacing the E-ring lactone by a ketone function are potent inhibitors of topoisomerase I and promising antitumor drugs.
Lansiaux A; Léonce S; Kraus-Berthier L; Bal-Mahieu C; Mazinghien R; Didier S; David-Cordonnier MH; Hautefaye P; Lavielle G; Bailly C; Hickman JA; Pierré A
Mol Pharmacol; 2007 Aug; 72(2):311-9. PubMed ID: 17494837
[TBL] [Abstract][Full Text] [Related]
11. Preclinical evaluation of the novel 7-substituted camptothecin Namitecan (ST1968) in paediatric tumour models.
Meco D; Di Francesco AM; Cusano G; Bucci F; Pierri F; Patriarca V; Torella AR; Pisano C; Riccardi R
Cancer Chemother Pharmacol; 2012 Dec; 70(6):811-22. PubMed ID: 23007316
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of ST1968 (namitecan) on a topotecan-resistant squamous cell carcinoma.
Zuco V; Supino R; Favini E; Tortoreto M; Cincinelli R; Croce AC; Bucci F; Pisano C; Zunino F
Biochem Pharmacol; 2010 Feb; 79(4):535-41. PubMed ID: 19765546
[TBL] [Abstract][Full Text] [Related]
13. Optimized synthesis and enhanced efficacy of novel triplex-forming camptothecin derivatives based on gimatecan.
Vekhoff P; Halby L; Oussedik K; Dallavalle S; Merlini L; Mahieu C; Lansiaux A; Bailly C; Boutorine A; Pisano C; Giannini G; Alloatti D; Arimondo PB
Bioconjug Chem; 2009 Apr; 20(4):666-72. PubMed ID: 19309124
[TBL] [Abstract][Full Text] [Related]
14. Tumor regression and curability of preclinical neuroblastoma models by PEGylated SN38 (EZN-2208), a novel topoisomerase I inhibitor.
Pastorino F; Loi M; Sapra P; Becherini P; Cilli M; Emionite L; Ribatti D; Greenberger LM; Horak ID; Ponzoni M
Clin Cancer Res; 2010 Oct; 16(19):4809-21. PubMed ID: 20702613
[TBL] [Abstract][Full Text] [Related]
15. DNA-topoisomerase I, a new target for the treatment of neuroblastoma.
Vassal G; Pondarré C; Cappelli C; Terrier-Lacombe MJ; Boland I; Morizet J; Bénard J; Vénuat AM; Ardouin P; Hartmann O; Gouyette A
Eur J Cancer; 1997 Oct; 33(12):2011-5. PubMed ID: 9516844
[TBL] [Abstract][Full Text] [Related]
16. A chemical screen identifies the chemotherapeutic drug topotecan as a specific inhibitor of the B-MYB/MYCN axis in neuroblastoma.
Sottile F; Gnemmi I; Cantilena S; D'Acunto WC; Sala A
Oncotarget; 2012 May; 3(5):535-45. PubMed ID: 22619121
[TBL] [Abstract][Full Text] [Related]
17. Chimmitecan, a novel 9-substituted camptothecin, with improved anticancer pharmacologic profiles in vitro and in vivo.
Huang M; Gao H; Chen Y; Zhu H; Cai Y; Zhang X; Miao Z; Jiang H; Zhang J; Shen H; Lin L; Lu W; Ding J
Clin Cancer Res; 2007 Feb; 13(4):1298-307. PubMed ID: 17287296
[TBL] [Abstract][Full Text] [Related]
18. Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines.
Keshelava N; Groshen S; Reynolds CP
Cancer Chemother Pharmacol; 2000; 45(1):1-8. PubMed ID: 10647494
[TBL] [Abstract][Full Text] [Related]
19. Next generation topoisomerase I inhibitors: Rationale and biomarker strategies.
Teicher BA
Biochem Pharmacol; 2008 Mar; 75(6):1262-71. PubMed ID: 18061144
[TBL] [Abstract][Full Text] [Related]
20. Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan, and CPT-11 studied in the mouse cornea model.
O'Leary JJ; Shapiro RL; Ren CJ; Chuang N; Cohen HW; Potmesil M
Clin Cancer Res; 1999 Jan; 5(1):181-7. PubMed ID: 9918217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
